InpharmD vs Micromedex (2026)
A reference product against a service, and that distinction is the decision. Micromedex is a curated drug and toxicology reference with AI search over it, recognized by CMS as a drug compendium and used in more than 80 countries. InpharmD answers the question a clinician actually asked. A pharmacist turns it into a researchable question, language models draft a literature summary, and a board certified drug information pharmacist reviews the draft before it goes back. It sells mainly to pharmacy and therapeutics committees, with drug monographs, class reviews and formulary support. For an interaction or a dose right now, the reference wins. For a formulary question the reference does not cover, InpharmD does work Micromedex does not attempt.
- A board certified drug information pharmacist reviews every answer before it reaches the clinician.
- A published pipeline showing where the model works and where the pharmacist does.
- A free pilot with a 30 day calibration period, and a stated SOC 2 Type II environment.
- Recognized by CMS as a drug compendium, which reaches coverage decisions as well as clinical ones.
- Answers in seconds, with a citation on every AI search result that opens the source in one click.
- Business associate status stated in Merative's contract terms, where InpharmD asks users not to submit patient information.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. InpharmD and Micromedex are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | InpharmD | Micromedex |
|---|---|---|
| Primary category | Clinical Reference & Evidence | Clinical Reference & Evidence |
| Headquarters | Atlanta, Georgia | Ann Arbor, Michigan |
| Website | inpharmd.com | merative.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Drug information service delivered as software, from an Atlanta company operating since at least 2014. Cofounders Ashish Advani, a pharmacist and the chief executive, and Tulasee Rao Chintha, chief technology officer. The company's own framing is drug information pharmacists without adding full time staff: a health system's clinical pharmacists ask any question, at any time, and receive a custom literature search and answer, so they can practice at the top of their license.
Source: AI Health Index, September 2026
Drug and toxicology reference from Merative, the company formed in June 2022 when Francisco Partners acquired the Watson Health assets from IBM. Headquartered in Ann Arbor, Michigan; Merative chief executive Gerry McCarthy, with Sonika Mathur as general manager for Micromedex. Content is curated by clinical experts from primary literature with in line referencing and daily updates, and is used in more than 80 countries by providers, poison control centers, government departments, universities, pharmaceutical organizations and health plans.
Source: AI Health Index, September 2026
Questions buyers ask
How do InpharmD and Micromedex work with the EHR?
For InpharmD, the FAQ says that because the company takes no protected health information, a health system does not have to integrate, though the company can integrate with the customer's EHR and wholesaler.
Merative states that Micromedex integrates with existing electronic health records, pharmacy benefit management systems and clinical processes, and customer feedback collected by KLAS praises integration and interoperability, with one customer describing a long standing deployment. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
How are InpharmD and Micromedex priced and sold?
In InpharmD's case, the pilot page sets out the route: a meeting to establish fit, then a free pilot with a 30 day calibration period aligning the service to the health system's templates, workflows, formulary and style guide, while the company compiles the customer's data into an internal business case.
Merative publishes no price, tier, unit, pricing basis or implementation fee for Micromedex, and no position on whether the AI search is included in an existing subscription or sold as an addition; every route on its material leads to a contact or demonstration request, with no self serve tier or published trial for the clinician product. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
How do InpharmD and Micromedex handle patient data?
With InpharmD, the privacy policy (effective May 2026) tells users not to submit protected health information, financial information or other sensitive personal information about themselves or anyone else, and says that if protected health information is submitted inadvertently the company assumes no responsibility for its handling under HIPAA. The FAQ says the company does not take protected health information.
In Micromedex's case, the clinician reference needs no patient record to work; the payer offering, which supports coverage determinations and claims adjudication, sits closer to member data, and the boundary is not described. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
What evidence is published for InpharmD and Micromedex?
The home page and FAQ state that more than 30 health systems retain an InpharmD virtual drug information pharmacist, that the service is trusted by more than 20,000 clinical pharmacists, 161,050 clinical pharmacist hours saved, a return on investment of more than four times, and a 100 percent customer satisfaction rate.
With Micromedex, the peer reviewed study measured usability rather than correctness, evaluated an earlier assistant two years before the current AI search, and was coauthored by the vendor; KLAS measures customer experience, and the compendium designation covers content rather than the model built over it. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both records were reviewed on this site in September 2026. Neither publishes a price or an accuracy measurement. InpharmD's figures, including more than 30 health systems and 161,050 pharmacist hours saved, are its own and carry no method.
Ask InpharmD for its turnaround time distribution rather than its average, and ask Merative for the results behind its AI search validation.